
|Articles|December 3, 2012
FDA approves cabozantinib to treat rare type of thyroid cancer
FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Targeted Coordination Is Crucial in Boosting Pneumococcal Vaccine Coverage
2
Q&A: Community Pharmacists Educate Patients on Safe Insulin Use
3
Scripted for Her: HRT Black Box Removal
4
Trump Executive Order Set to Reclassify Marijuana, Improve CBD Access
5
















































































































